Baker Daniel G. 4

What Happened

• Daniel G. Baker, Chief Development Officer of Cue Biopharma (CUE), was granted a derivative award for 100,000 shares on 2026-04-09. The reported acquisition price is $0.00, so no cash was paid at grant. This filing reports an award/grant (not a market purchase or a sale).

Key Details

• Transaction date: 2026-04-09; Filing date (Form 4): 2026-04-10 (timely).
• Transaction type: Award/Grant (derivative) — 100,000 shares at $0.00.
• Shares owned after transaction: Not disclosed in the provided data.
• Footnote: The award becomes exercisable over four years — 25% vests on the one-year anniversary of the grant, with the remainder vesting in equal semi-annual installments thereafter.
• No sale or exercise reported in this filing; this appears to be a standard compensation grant (not a 10b5-1 trade or gift).

Context

• This is a compensation grant that vests over time; such awards are common for retention and incentive purposes and do not necessarily signal immediate insider buying or selling. Because the reported acquisition price is $0.00 and the grant is a derivative award, the future economic value to the insider will depend on vesting and any future exercise conditions or share delivery events. Monitor future Form 4s for vesting, exercises, or any subsequent sales.